MCID: SML011
MIFTS: 32

Smoldering Myeloma

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Smoldering Myeloma

MalaCards integrated aliases for Smoldering Myeloma:

Name: Smoldering Myeloma 12 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9551
UMLS 70 C1531608

Summaries for Smoldering Myeloma

Disease Ontology : 12 A multiple myeloma that is a slow growing type of myeloma in which abnormal plasma cells results in too much of a single type of monoclonal antibody.

MalaCards based summary : Smoldering Myeloma is related to plasmacytoma and plasma cell neoplasm, and has symptoms including bone pain An important gene associated with Smoldering Myeloma is CD274 (CD274 Molecule), and among its related pathways/superpathways are NF-kappaB Signaling and Cell adhesion molecules. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid.

Related Diseases for Smoldering Myeloma

Diseases related to Smoldering Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Related Disease Score Top Affiliating Genes
1 plasmacytoma 30.0 NCAM1 CD38 B2M
2 plasma cell neoplasm 29.6 SDC1 MYOM2 IGHV4-38-2 FGFR3 B2M
3 bone marrow cancer 28.6 SLAMF7 SDC1 NSD2 NCAM1 MYOM2 IGHV4-38-2
4 myeloma, multiple 28.4 TENT5C SLAMF7 SDC1 NSD2 NCAM1 MYOM2
5 monoclonal gammopathy of uncertain significance 28.2 TENT5C SLAMF7 SDC1 NSD2 NCAM1 MYOM2
6 glomeruloid hemangioma 10.3 SDC1 MYOM2
7 amyloid tumor 10.3 MYOM2 B2M
8 mental retardation, autosomal dominant 36 10.3 SDC1 CD38
9 heavy chain disease 10.3 MYOM2 IGHV4-38-2
10 plasmablastic lymphoma 10.3 SLAMF7 CD38
11 t-cell non-hodgkin lymphoma 10.3 CD274 B2M
12 tracheal lymphoma 10.2 SDC1 IGHV4-38-2
13 composite lymphoma 10.2 IGHV4-38-2 CD274
14 testicular lymphoma 10.2 IGHV4-38-2 CD274
15 mental retardation, autosomal dominant 33 10.2 IGHV4-38-2 CD38
16 chromosome 13q14 deletion syndrome 10.2 IGHV4-38-2 CD38
17 spherocytosis, type 5 10.2 SDC1 CD38
18 amyloidosis 10.2
19 gamma heavy chain disease 10.1 SDC1 IGHV4-38-2 CD38
20 mental retardation, autosomal dominant 10 10.1 SDC1 IGHV4-38-2 CD38
21 schuurs-hoeijmakers syndrome 10.1 IGHV4-38-2 CD38
22 b-cell expansion with nfkb and t-cell anergy 10.1 CD38 B2M
23 mulchandani-bhoj-conlin syndrome 10.1 SDC1 CD38
24 extramedullary plasmacytoma 10.1 SDC1 MYOM2 CD38 B2M
25 lymphoma, mucosa-associated lymphoid type 10.1 SDC1 IGHV4-38-2 B2M
26 scleredema adultorum 10.1
27 end stage renal disease 10.1
28 nasal cavity benign neoplasm 10.1 SDC1 NCAM1 MYOM2
29 diffuse large b-cell lymphoma 10.1 SDC1 CD38 CD274 B2M
30 infected hydrocele 10.0 SDC1 NCAM1 B2M
31 monoclonal paraproteinemia 10.0 SDC1 NCAM1 IGHV4-38-2
32 cll/sll 10.0 IGHV4-38-2 CD38
33 nasal cavity lymphoma 10.0 NCAM1 IGHV4-38-2 B2M
34 human immunodeficiency virus infectious disease 9.9 NCAM1 CD38 B2M
35 atherosclerosis susceptibility 9.9
36 type 2 diabetes mellitus 9.9
37 scleroderma, familial progressive 9.9
38 sickle cell anemia 9.9
39 deficiency anemia 9.9
40 pulmonary hypertension 9.9
41 bone disease 9.9
42 non-alcoholic steatohepatitis 9.9
43 poems syndrome 9.9
44 acute kidney failure 9.9
45 skin disease 9.9
46 liver cirrhosis 9.9
47 progressive multifocal leukoencephalopathy 9.9
48 septic arthritis 9.9
49 arthritis 9.9
50 light chain deposition disease 9.9

Graphical network of the top 20 diseases related to Smoldering Myeloma:



Diseases related to Smoldering Myeloma

Symptoms & Phenotypes for Smoldering Myeloma

UMLS symptoms related to Smoldering Myeloma:


bone pain

Drugs & Therapeutics for Smoldering Myeloma

Drugs for Smoldering Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
3
Lenalidomide Approved Phase 3 191732-72-6 216326
4
Ichthammol Approved Phase 3 8029-68-3
5
Daratumumab Approved Phase 3 945721-28-8
6 Gastrointestinal Agents Phase 3
7 Angiogenesis Inhibitors Phase 3
8 Hormone Antagonists Phase 3
9 Antiemetics Phase 3
10 glucocorticoids Phase 3
11 Hormones Phase 3
12 Immunologic Factors Phase 3
13 Antineoplastic Agents, Hormonal Phase 3
14 BB 1101 Phase 3
15 Anti-Inflammatory Agents Phase 3
16
protease inhibitors Phase 3
17 Dermatologic Agents Phase 3
18 HIV Protease Inhibitors Phase 3
19 Antibodies Phase 3
20 Immunoglobulins Phase 3
21 Antibodies, Monoclonal Phase 3
22
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
23
Elotuzumab Approved Phase 2 915296-00-3
24
Denosumab Approved Phase 2 615258-40-7
25
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
27
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
28 Analgesics, Non-Narcotic Phase 2
29 Cyclooxygenase 2 Inhibitors Phase 2
30 Analgesics Phase 2
31 Cyclooxygenase Inhibitors Phase 2
32 Antirheumatic Agents Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 2
34 Pharmaceutical Solutions Phase 2
35 Vitamins Phase 2
36 Calciferol Phase 2
37 Calcium, Dietary Phase 2
38
Calcium Nutraceutical Phase 2 7440-70-2 271
39
Altretamine Approved Early Phase 1 645-05-6 2123
40 Plasma-lyte 148 Early Phase 1
41 Vaccines Early Phase 1

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Recruiting NCT03937635 Phase 3 Dexamethasone;Lenalidomide
2 Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
3 A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma Completed NCT01441973 Phase 2
4 E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT02279394 Phase 2 Elotuzumab;Lenalidomide;Dexamethasone
5 Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial "DEFENCE" (DEnosumab For the rEductioN of the Smoldering Myeloma transformatioN inCidence ratE) Active, not recruiting NCT03792763 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA];Placebo 1.7 ml Subcutaneous Solution
6 Iberdomide in Intermediate- and High-Risk Smoldering Myeloma (SMM) Patients: A Phase 2 Study With a Safety Run-in Not yet recruiting NCT04776395 Phase 2 Dexamethasone;Iberdomide Hydrochloride
7 B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma Not yet recruiting NCT04775550 Phase 2 Daratumumab;Bortezomib;Lenalidomide;Dexamethasone
8 Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients Terminated NCT00983346 Phase 2 Bortezomib
9 A Phase II Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma Terminated NCT01302366 Phase 2 TBL12
10 Evaluation of the Impact of the Update Multiple Myeloma Criteria on the Natural History of Smoldering Myeloma in Order to Establish New Recommendations About Follow-up and Prognostic Evaluation of Smoldering Myeloma (CARRISMM) Recruiting NCT04144387
11 Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey Recruiting NCT04727294
12 A Pilot Study of Dendritic Cell DKK1 Vaccine for Patients With Monoclonal Gammopathy and Stable or Smoldering Myeloma Not yet recruiting NCT03591614 Early Phase 1
13 Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) Terminated NCT01109407

Search NIH Clinical Center for Smoldering Myeloma

Genetic Tests for Smoldering Myeloma

Anatomical Context for Smoldering Myeloma

MalaCards organs/tissues related to Smoldering Myeloma:

40
Bone, Bone Marrow, Myeloid, Monocytes, T Cells, Temporal Lobe

Publications for Smoldering Myeloma

Articles related to Smoldering Myeloma:

(show top 50) (show all 191)
# Title Authors PMID Year
1
[Multiple myeloma-soon curable?] 61
33783581 2021
2
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. 61
33767199 2021
3
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA. 61
33107092 2021
4
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. 61
32235256 2021
5
Assessment of atherosclerosis in multiple myeloma and smoldering myeloma patients using 18F- sodium fluoride PET/CT. 61
33389640 2021
6
Epidemiology, Staging, and Management of Multiple Myeloma. 61
33498356 2021
7
Kidney transplantation for active multiple myeloma or smoldering myeloma: a case-control study. 61
33564414 2021
8
Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma. 61
32621061 2021
9
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. 61
33436579 2021
10
Cancer immunoediting and immune dysregulation in multiple myeloma. 61
32645135 2020
11
Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. 61
33187184 2020
12
Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas. 61
33180138 2020
13
Practical approach to the management of smoldering myeloma. 61
32890022 2020
14
Increased Risk of Cutaneous Diseases in Multiple Myeloma Patients. 61
33062479 2020
15
How we manage smoldering multiple myeloma. 61
33042502 2020
16
The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. 61
32825035 2020
17
Smoldering Myeloma and the Art of War. 61
32463739 2020
18
Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. 61
32376310 2020
19
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. 61
33409501 2020
20
Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. 61
32290723 2020
21
Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. 61
32456143 2020
22
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. 61
32027747 2020
23
Recent Advances in the Management of Smoldering Multiple Myeloma. 61
32284772 2020
24
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications. 61
32160077 2020
25
Clinical Controversies in the Management of Smoldering Multiple Myeloma. 61
32223666 2020
26
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. 61
32139017 2020
27
Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. 61
32139013 2020
28
The Role of Early Intervention in High-Risk Smoldering Myeloma. 61
32182141 2020
29
Therapeutic Advances in the Management of Smoldering Myeloma. 61
31842112 2020
30
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. 61
31830214 2020
31
Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. 61
32075123 2020
32
Multiple Myeloma in the Time of COVID-19. 61
32305989 2020
33
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. 61
32904669 2020
34
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients. 61
33488620 2020
35
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient. 61
33042520 2020
36
Reversal of skin changes in smoldering myeloma with clinical presentation of POEMS syndrome with a lenalidomide-based regimen. 61
31650288 2019
37
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. 61
31590151 2019
38
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. 61
31541083 2019
39
Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: A renal biopsy and autopsy case report. 61
31574818 2019
40
Manasanch EE, Han G, Mathur R, et al. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv. 2019;3(15):2400-2408. 61
31515233 2019
41
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. 61
31405950 2019
42
Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. 61
30973821 2019
43
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression. 61
31053880 2019
44
Timing treatment for smoldering myeloma: is earlier better? 61
30907176 2019
45
Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. 61
30511139 2019
46
Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. 61
30787429 2019
47
Scleredema associated with immunoglobulin A-κ smoldering myeloma: a case report and review of the literature. 61
31084620 2019
48
State of the science in smoldering myeloma: Should we be treating in the clinic? 61
31072611 2019
49
Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. 61
30845779 2019
50
Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma. 61
30315756 2018

Variations for Smoldering Myeloma

Expression for Smoldering Myeloma

Search GEO for disease gene expression data for Smoldering Myeloma.

Pathways for Smoldering Myeloma

Pathways related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.54 NCAM1 LAG3 CD38 CD274 B2M
2 11.51 SDC1 NCAM1 CD274
3 11.2 SDC1 NCAM1 CD38

GO Terms for Smoldering Myeloma

Cellular components related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 SDC1 NCAM1 FGFR3 CD38 CD274 B2M
2 external side of plasma membrane GO:0009897 9.1 SDC1 NCAM1 LAG3 IGHV4-38-2 CD274 B2M

Molecular functions related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 SLAMF7 SDC1 NCAM1 MAFB FGFR3 CD38

Sources for Smoldering Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....